Search

Displaying results 5161 - 5170 of 7180 in total
  1. Drug

    Stamulumab

    go.drugbank.com/drugs/DB05915
    Investigational

    MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.

  2. Drug

    Coronavirus-Like Particle COVID-19 Vaccine

    go.drugbank.com/drugs/DB15852
    Experimental

    In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as [ISS-1018]), meant to provide an enhanced immune response to the vaccine. … In addition, Medicago partnered with GlaxoSmithKline (GSK) to test its adjuvant, AS03.

  3. Drug

    Custirsen

    go.drugbank.com/drugs/DB05487
    Investigational

    Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth a...

  4. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...

  5. Drug

    Treamid

    go.drugbank.com/drugs/DB16365
    Investigational

    It is has been investigated in the clinical trials of NCT04428593 (Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers) and NCT04527354 (Pilot Study to Assess Efficacy … and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia) by PHARMENTERPRISES.

  6. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    It also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2[A226853]. … These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants.

  7. Drug

    Vanillic acid

    go.drugbank.com/drugs/DB02130
    Experimental

    It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).

  8. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  9. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, [GC-376 free acid][A219031,A219036]. … GC-373 has been shown to inhibit the M<sup>pro</sup> target in various coronavirus strains, including feline, mink, and ferret M<sup>pro</sup> [A219041].

  10. Drug

    TP-252

    go.drugbank.com/drugs/DB17912
    Experimental

    TP-252 consists of magnesium L-lysinate bis-eicosapentaenoate, an ionizable salt of eicosapentaenoic acid (EPA), currently being investigated to treat familial adenomatous polyposis.[A259956]

    Synonyms: Magnesium, bis(l-lysinato-.kappa.n2,.kappa.o1)-, (t-4)-, (5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaenoate (1:2)